Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024ORION CORPORATION PRESS RELEASE 26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024Orion presented yesterday at the 2024 ASCO GU Cancers Symposium a poster with additional data from the ongoing Phase II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5684), an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations. Previously published data has focused on patients with androgen receptor gene (AR) ligand-binding-domain (LBD) mutations. The new data reports initial results in an extension cohort of mainly AR-LBD wild-type patients combined with previously reported phase 2 data (AR-LBD mutation-positive only).
Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate CancerORION CORPORATION PRESS RELEASE05 JANUARY 2023 at 13:45 EET Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208ORION CORPORATION PRESS RELEASE 27 DECEMBER 2023 at 11:00 EET NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
Orion Research Foundation grants EUR 1,112,000 for research in 2024Orion Research Foundation grants EUR 1,112,000 for research in 2024
Orion and Bayer expand clinical development program for darolutamide in prostate cancerORION CORPORATION PRESS RELEASE 23 March 2023 at 15:00 EET Orion and Bayer expand clinical development program for darolutamide in prostate cancer
Darolutamide approved for additional prostate cancer indication in ChinaORION CORPORATION PRESS RELEASE 20 March 2023 at 09:00 EET Darolutamide approved for additional prostate cancer indication in China
Darolutamide receives EU approval for additional indication in prostate cancerORION CORPORATION PRESS RELEASE 1 March 2023 at 13:00 EET Darolutamide receives EU approval for additional indication in prostate cancer
Darolutamide receives approval for additional prostate cancer indication in JapanORION CORPORATION PRESS RELEASE 27 February 2023 at 9:00 EET Darolutamide receives approval for additional prostate cancer indication in Japan
Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancerORION CORPORATION PRESS RELEASE 27 January 2023 at 14:00 EET Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer
